Further, we show that EZH2 overexpression tracks with independently verified immunohistologic identification in our 226-case study on breast carcinoma, particularly identifying essentially all triple-negative cases and a large proportion of high-grade HER2-positive cases. Here, EZH2 is linked to breast carcinoma.